Generalized social anxiety disorder: A still-neglected anxiety disorder 3 decades since Liebowitz's review

Psychiatry and Clinical Neurosciences

Volumn 69, Issue 12, 2015, Pages 724-740

  Nagata, Toshihiko ^a   Suzuki, Futoshi ^b   Teo, Alan R ^c  

^a SAN EI Midosuji Bldg 3F ^*  (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

generalized; social anxiety disorder; taijin kyofusho; under recognition; undertreatment

Indexed keywords

ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUVOXAMINE; GABAPENTIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PHENELZINE; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGORAPHOBIA; AMYGDALOID NUCLEUS; ANTISOCIAL PERSONALITY DISORDER; AUTISM; BORDERLINE STATE; CHRONIC DISEASE; CULTURAL FACTOR; DEPRESSION; DSM-III; DSM-IV; FIRST DEGREE RELATIVE; GENETIC PREDISPOSITION; HUMAN; IMPULSIVENESS; JAPANESE (PEOPLE); LIEBOWITZ SOCIAL ANXIETY SCALE; NEGLECTED DISEASE; NEUROIMAGING; PANIC; PERFORMANCE ANXIETY; PERSONALITY DISORDER; PREVALENCE; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL WITHDRAWAL; PSYCHOTHERAPY; PUBLIC SPEAKING; REVIEW; SCHIZOPHRENIA; SOCIAL PHOBIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SUBSTANCE ABUSE; ANXIETY DISORDERS; AUSTRALIA; AUTISM SPECTRUM DISORDER; CANADA; COMORBIDITY; DEPRESSIVE DISORDER; EUROPE; FAR EAST; MIDDLE EAST; NIGERIA; PANIC DISORDER; PERSONALITY DISORDERS; PHOBIC DISORDERS; PSYCHOLOGY; SOUTH AFRICA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

AGORAPHOBIA; ANXIETY DISORDERS; AUSTRALIA; AUTISM SPECTRUM DISORDER; CANADA; COMORBIDITY; DEPRESSIVE DISORDER; EUROPE; FAR EAST; HUMANS; MIDDLE EAST; NIGERIA; PANIC DISORDER; PERSONALITY DISORDERS; PHOBIC DISORDERS; SCHIZOPHRENIA; SOUTH AFRICA; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84937795085     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12327     Document Type: Review

References (147)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. American Psychiatric Publishing, Washington, DC, 2013.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 1994; 51: 8-19.
3. Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC,. Social fears and social phobia in the USA: Results from the National Comorbidity Survey Replication. Psycho. Med 2008; 38: 15-28.
4. Stein MB, Stein DJ,. Social anxiety disorder. Lancet 2008; 371: 1115-1125.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. American Psychiatric Press, Washington, DC, 1980.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., Revised. American Psychiatric Press, Washington, DC, 1987.
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC, 1994.
8. Wakefield JC, Horwitz AV, Schmitz MF,. Are we overpathologizing the socially anxious? Social phobia from a harmful dysfunction perspective. Can. J. Psychiatry 2005; 50: 317-319.
9. Moynihan R, Henry D,. The fight against disease mongering: Generating knowledge for action. PLoS Med. 2006; 3: e191.
10. Wilson EO,. Biophilia. Harvard University Press, Cambridge, MA, 1984.
11. Hook JN, Valentiner DP,. Are specific and generalized social phobias qualitatively distinct? Clin. Psychol. Sci. Pract. 2002; 9: 379-395.
12. Zimmerman M, Chelminski I,. Clinician recognition of anxiety disorders in depressed outpatients. J. Psychiatr. Res. 2003; 37: 325-333.
13. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am. J. Psychiatry 2001; 158: 1999-2007.
14. Bogels SM, Alden L, Beidel DC, et al. Social anxiety disorder: Questions and answers for the DSM-V. Depress. Anxiety 2010; 27: 168-189.
15. Spitzer RL, First MB, Shedler J, Westen D, Skodol AE,. Clinical utility of five dimensional systems for personality diagnosis: A 'consumer preference' study. J. Nerv. Ment. Dis. 2008; 196: 356-374.
16. DeFife JA, Peart J, Bradley B, Ressler K, Drill R, Westen D,. Validity of prototype diagnosis for mood and anxiety disorders. JAMA Psychiatry 2013; 70: 140-148.
17. Marks IM, Gelder MG,. Different ages of onset in varieties of phobia. Am. J. Psychiatry 1966; 123: 218-221.
18. Greenberg D, Stravynski A,. Social phobia. Br. J. Psychiatry 1983; 143: 526-527.
19. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF,. Social phobia. Review of a neglected anxiety disorder. Arch. Gen. Psychiatry 1985; 42: 729-736.
20. El-Gabalawy R, Cox B, Clara I, Mackenzie C,. Assessing the validity of social anxiety disorder subtypes using a nationally representative sample. J. Anxiety Disord. 2010; 24: 244-249.
21. Stein MB, Torgrud LJ, Walker JR,. Social phobia symptoms, subtypes, and severity: Findings from a community survey. Arch. Gen. Psychiatry 2000; 57: 1046-1052.
22. Stein DJ, Ruscio AM, Lee S, et al. Subtyping social anxiety disorder in developed and developing countries. Depress. Anxiety 2010; 27: 390-403.
23. Cox BJ, Clara IP, Sareen J, Stein MB,. The structure of feared social situations among individuals with a lifetime diagnosis of social anxiety disorder in two independent nationally representative mental health surveys. Behav. Res. Ther. 2008; 46: 477-486.
24. Heimberg RG, Hope DA, Dodge CS, Becker RE,. DSM-III-R subtypes of social phobia. Comparison of generalized social phobics and public speaking phobics. J. Nerv. Ment. Dis. 1990; 178: 172-179.
25. Mannuzza S, Schneier FR, Chapman TF, Liebowitz MR, Klein DF, Fyer AJ,. Generalized social phobia. Reliability and validity. Arch. Gen. Psychiatry 1995; 52: 230-237.
26. Hofmann SG, Albano AM, Heimberg RG, Tracey S, Chorpita BF, Barlow DH,. Subtypes of social phobia in adolescents. Depress. Anxiety 1999; 9: 15-18.
27. Stein MB, Hazen AL,. Modified Version of Structured Clinical Interview for DSM-IV (SCID-P). Anxiety Disorders Research Program. University of California, San Diego, 1995.
28. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I,. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial. JAMA 1998; 280: 708-713.
29. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD,. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J. Clin. Psychiatry 2002; 63: 66-74.
30. Mennin DS, Fresco DM, Heimberg RG, Schneier FR, Davies SO, Liebowitz MR,. Screening for social anxiety disorder in the clinical setting: Using the Liebowitz Social Anxiety Scale. J. Anxiety Disord. 2002; 16: 661-673.
31. Chartrand H, Cox B, El-Gabalawy R, Clara I,. Social anxiety disorder subtypes and their mental health correlates in a nationally representative Canadian sample. Can. J. Behav. Sci. 2011; 43: 89-98.
32. Vorcaro C, Rocha F, Uchoa E, Lima-Costa M,. The burden of social phobia in a Brazilian community and its relationship with socioeconomic circumstances, health status and use of health services: The Bambui Study. Int. J. Soc. Psychiatry 2004; 50: 216-226.
33. Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S,. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am. J. Psychiatry 2006; 163: 1362-1370.
34. Bijl RV, Ravelli A, van Zessen G,. Prevalence of psychiatric disorder in the general population: Results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc. Psychiatry Psychiatr. Epidemiol. 1998; 33: 587-595.
35. Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 2005; 66: 1351-1361.
36. Medina-Mora ME, Borges G, Lara C, et al. Prevalence, service use, and demographic correlates of 12-month DSM-IV psychiatric disorders in Mexico: Results from the Mexican National Comorbidity Survey. Psychol. Med. 2005; 35: 1773-1783.
37. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. Suppl. 2004; 109: 21-27.
38. Florescu S, Moldovan M, Mihaescu-Pintia C, Ciutan M, Sorel GE,. The Mental Health Study Romania 2007. Prevalence, severity, and treatment of 12-month DSM-IV disorders. Manag. Health 2009; 4: 23-31.
39. Bromet EJ, Gluzman SF, Paniotto VI, et al. Epidemiology of psychiatric and alcohol disorders in Ukraine: Findings from the Ukraine World Mental Health survey. Soc. Psychiatry Psychiatr. Epidemiol. 2005; 40: 681-690.
40. Lampe L, Slade T, Issakidis C, Andrews G,. Social phobia in the Australian National Survey of Mental Health and Well-Being (NSMHWB). Psychol. Med. 2003; 33: 637-646.
41. Crome E, Grove R, Baillie AJ, Sunderland M, Teesson M, Slade T,. DSM-IV and DSM-5 social anxiety disorder in the Australian community. Aust. N. Z. J. Psychiatry 2014; 49: 227-235.
42. Wells JE, Browne MA, Scott KM, et al. Prevalence, interference with life and severity of 12 month DSM-IV disorders in Te Rau Hinengaro: The New Zealand Mental Health Survey. Aust. N. Z. J. Psychiatry 2006; 40: 845-854.
43. Kawakami N, Takeshima T, Ono Y, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: Preliminary finding from the World Mental Health Japan Survey 2002-2003. Psychiatry Clin. Neurosci. 2005; 59: 441-452.
44. Kawakami N,. Japanese Psychiatric Epidemiology: World Mental Health Japan Survey Second. Labour and Welfare Ministry, Tokyo, 2014.
45. Shen YC, Zhang MY, Huang YQ, et al. Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China. Psychol. Med. 2006; 36: 257-267.
46. Cho MJ, Kim JK, Jeon HJ, et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J. Nerv. Ment. Dis. 2007; 195: 203-210.
47. Williams DR, Herman A, Stein DJ, et al. Twelve-month mental disorders in South Africa: Prevalence, service use and demographic correlates in the population-based South African Stress and Health Study. Psychol. Med. 2008; 38: 211-220.
48. Gureje O, Lasebikan VO, Kola L, Makanjuola VA,. Lifetime and 12-month prevalence of mental disorders in the Nigerian Survey of Mental Health and Well-Being. Br. J. Psychiatry 2006; 188: 465-471.
49. Karam EG, Mneimneh ZN, Karam AN, et al. Prevalence and treatment of mental disorders in Lebanon: A national epidemiological survey. Lancet 2006; 367: 1000-1006.
50. Capps D,. Cultural dimensions of social phobia. In:, Capps D, (ed.). Social Phobia, Alleviation Anxiety in an Age of Self-Promotion. Chalice Press, St. Louis, 1999; 127-139.
51. Heimberg RG, Stein MB, Hiripi E, Kessler RC,. Trends in the prevalence of social phobia in the United States: A synthetic cohort analysis of changes over four decades. Eur. Psychiatry 2000; 15: 29-37.
52. CIMA Science Journal. Ai Report 2011. CIMA Science Journal, Tokyo, 2011.
53. Sim K, Lee NB, Chua HC, et al. Newer antidepressant drug use in East Asian psychiatric treatment settings: REAP (Research on East Asia Psychotropic Prescriptions) Study. Br. J. Clin. Pharmacol. 2007; 63: 431-437.
54. Burstein M, He JP, Kattan G, Albano AM, Avenevoli S, Merikangas KR,. Social phobia and subtypes in the national comorbidity survey-adolescent supplement: Prevalence, correlates, and comorbidity. J. Am. Acad. Child Adolesc. Psychiatry 2011; 50: 870-880.
55. Kerns CE, Comer JS, Pincus DB, Hofmann SG,. Evaluation of the proposed social anxiety disorder specifier change for DSM-5 in a treatment-seeking sample of anxious youth. Depress. Anxiety 2013; 30: 709-715.
56. Wagner R, Silove D, Marnane C, Rouen D,. Delays in referral of patients with social phobia, panic disorder and generalized anxiety disorder attending a specialist anxiety clinic. J. Anxiety Disord. 2006; 20: 363-371.
57. Dalrymple KL, Zimmerman M,. Differences in clinical presentation between depressed outpatients wanting versus not wanting treatment for comorbid social anxiety disorder. J. Nerv. Ment. Dis. 2008; 196: 639-642.
58. Stein DJ,. Social anxiety disorder in the West and in the East. Ann. Clin. Psychiatry 2009; 21: 109-117.
59. Kitanishi K, Mori A,. Morita therapy: 1919 to 1995. Psychiatry Clin. Neurosci. 1995; 49: 245-254.
60. Kasahara Y, Fujinawa A, Sekiguchi H, Matsumoto M,. Fear of Eye-to-eye Confrontation and Fear of Emitting Bad Odors. Igaku Shoin, Tokyo, 1972 (in Japanese).
61. Yamashita I,. Taijin-Kyofu. Kanahara, Tokyo, 1977 (in Japanese).
62. Nagata T, Oshima J, Wada A, Yamada H, Iketani T, Kiriike N,. Open trial of milnacipran for Taijin Kyofusho in Japanese patients with social anxiety disorder. Int. J. Psychiatry Clin. Pract. 2003; 7: 107-112.
63. Nagata T, van Vliet I, Yamada H, Kataoka K, Iketani T, Kiriike N,. An open trial of paroxetine for the 'offensive subtype' of taijin kyofusho and social anxiety disorder. Depress. Anxiety 2006; 23: 168-174.
64. Takahashi T,. Social phobia syndrome in Japan. Compr. Psychiatry 1989; 30: 45-52.
65. Kirmayer LJ,. The place of culture in psychiatric nosology: Taijin kyofusho and DSM-III-R. J. Nerv. Ment. Dis. 1991; 179: 19-28.
66. Choy Y, Schneier FR, Heimberg RG, Oh KS, Liebowitz MR,. Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder. Depress. Anxiety 2008; 25: 230-240.
67. Kim J, Rapee RM, Gaston JE,. Symptoms of offensive type Taijin-Kyofusho among Australian social phobics. Depress. Anxiety 2008; 25: 601-608.
68. Heimberg RG, Hofmann SG, Liebowitz MR, et al. Social anxiety disorder in DSM-5. Depress. Anxiety 2014; 31: 472-479.
69. Kleinknecht RA, Dinnel DL, Kleinknecht EE, Hiruma N, Harada N,. Cultural factors in social anxiety: A comparison of social phobia symptoms and Taijin kyofusho. J. Anxiety Disord. 1997; 11: 157-177.
70. Heinrichs N, Rapee RM, Alden LA, et al. Cultural differences in perceived social norms and social anxiety. Behav. Res. Ther. 2006; 44: 1187-1197.
71. Okano K,. Shame and social phobia: A transcultural viewpoint. Bull. Menninger Clin. 1994; 58: 323-338.
72. Chen X, Rubin KH, Li B,. Social and school adjustment of shy and aggressive children in China. Dev. Psychopathol. 1995; 7: 337-349.
73. Nagata T, Oshima J, Wada A, et al. Social value in the patients with social anxiety disorder: Relationship with offensive subtype. Seishin Igaku 2004; 46: 141-147 (in Japanese).
74. Stemberger RT, Turner SM, Beidel DC, Calhoun KS,. Social phobia: An analysis of possible developmental factors. J. Abnorm. Psychol. 1995; 104: 526-531.
75. Bruch MA, Heimberg RG,. Differences in perceptions of parental and personal characteristics between generalized and nongeneralized social phobics. J. Anxiety Disord. 1994; 8: 155-168.
76. Knappe S, Beesdo-Baum K, Fehm L, Stein MB, Lieb R, Wittchen HU,. Social fear and social phobia types among community youth: Differential clinical features and vulnerability factors. J. Psychiatr. Res. 2011; 45: 111-120.
77. Hofmann SG, Ehlers A, Roth WT,. Conditioning theory-A model for the etiology of public speaking anxiety. Behav. Res. Ther. 1995; 33: 567-571.
78. Levin AP, Saoud JB, Strauman T, et al. Responses of generalized and discrete social phobics during public speaking. J. Anxiety Disord. 1993; 7: 207-221.
79. Boone ML, McNeil DW, Masia CL, et al. Multimodal comparisons of social phobia subtypes and avoidant personality disorder. J. Anxiety Disord. 1999; 13: 271-292.
80. Craske MG,. Phobic fear and panic attacks-The same emotional states triggered by different cues. Clin. Psychol. Rev. 1991; 11: 599-620.
81. McTeague LM, Lang PJ,. The anxiety spectrum and the reflex physiology of defense: From circumscribed fear to broad distress. Depress. Anxiety 2012; 29: 264-281.
82. Stein MB, Chartier MJ, Hazen AL, et al. A direct-interview family study of generalized social phobia. Am. J. Psychiatry 1998; 155: 90-97.
83. Tillfors M, Furmark T, Ekselius L, Fredrikson M,. Social phobia and avoidant personality disorder as related to parental history of social anxiety: A general population study. Behav. Res. Ther. 2001; 39: 289-298.
84. Kendler KS, Myers J, Prescott CA, Neale MC,. The genetic epidemiology of irrational fears and phobias in men. Arch. Gen. Psychiatry 2001; 58: 257-265.
85. Distel MA, Vink JM, Willemsen G, Middeldorp CM, Merckelbach HL, Boomsma DI,. Heritability of self-reported phobic fear. Behav. Genet. 2008; 38: 24-33.
86. Andrews G, Stewart G, Morris-Yates A, Holt P, Henderson S,. Evidence for a general neurotic syndrome. Br. J. Psychiatry 1990; 157: 6-12.
87. Merikangas KR, Avenevoli S, Dierker L, Grillon C,. Vulnerability factors among children at risk for anxiety disorders. Biol. Psychiatry 1999; 46: 1523-1535.
88. Hudson JL, Rapee RM,. The origins of social phobia. Behav. Modif. 2000; 24: 102-129.
89. Fouche JP, van Der Wee NJ, Roelofs K, Stein DJ,. Recent advances in the brain imaging of social anxiety disorder. Hum. Psychopharmacol. 2013; 28: 102-105.
90. Bruhl AB, Delsignore A, Komossa K, Weidt S,. Neuroimaging in social anxiety disorder-a meta-analytic review resulting in a new neurofunctional model. Neurosci. Biobehav. Rev. 2014; 47: 260-280.
91. Liebowitz MR,. Update on the diagnosis and treatment of social anxiety disorder. J. Clin. Psychiatry 1999; 60: 22-26.
92. Kessler RC, Stein MB, Berglund P,. Social phobia subtypes in the national comorbidity survey. Am. J. Psychiatry 1998; 155: 613-619.
93. Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch. Gen. Psychiatry 2007; 64: 903-912.
94. Randall CL, Thomas S, Thevos AK,. Concurrent alcoholism and social anxiety disorder: A first step toward developing effective treatments. Alcohol. Clin. Exp. Res. 2001; 25: 210-220.
95. Cox BJ, Pagura J, Stein MB, Sareen J,. The relationship between generalized social phobia and avoidant personality disorder in a national mental health survey. Depress. Anxiety 2009; 26: 354-362.
96. Marques L, Porter E, Keshaviah A, et al. Avoidant personality disorder in individuals with generalized social anxiety disorder: What does it add? J. Anxiety Disord. 2012; 26: 665-672.
97. Koyama A, Miyake Y, Kawakami N, Tsuchiya M, Tachimori H, Takeshima T,. Lifetime prevalence, psychiatric comorbidity and demographic correlates of 'hikikomori' in a community population in Japan. Psychiatry Res. 2010; 176: 69-74.
98. Nagata T, Yamada H, Teo AR, Yoshimura C, Nakajima T, van Vliet I,. Comorbid social withdrawal (hikikomori) in outpatients with social anxiety disorder: Clinical characteristics and treatment response in a case series. Int. J. Soc. Psychiatry 2013; 59: 73-78.
99. Keshavan MS, Duggal HS, Veeragandham G, et al. Personality dimensions in first-episode psychoses. Am. J. Psychiatry 2005; 162: 102-109.
100. Kashdan TB, McKnight PE,. The darker side of social anxiety: When aggressive impulsivity prevails over shy inhibition. Curr. Dir. Psychol. Sci. 2010; 19: 47-50.
101. Galbraith T, Heimberg RG, Wang S, Schneier FR, Blanco C,. Comorbidity of social anxiety disorder and antisocial personality disorder in the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J. Anxiety Disord. 2014; 28: 57-66.
102. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am. J. Psychiatry 1998; 155: 1733-1739.
103. Nagata T, Kawarada Y, Kiriike N, Iketani T,. Multi-impulsivity of Japanese patients with eating disorders: Primary and secondary impulsivity. Psychiatry Res. 2000; 94: 239-250.
104. Montgomery SA,. Implications of the severity of social phobia. J. Affect. Disord. 1998; 50 (Suppl. 1): S17-S22.
105. Stein DJ, Baldwin DS, Bandelow B, et al. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr. Psychiatry Rep. 2010; 12: 471-477.
106. March JS, Entusah AR, Rynn M, Albano AM, Tourian KA,. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol. Psychiatry 2007; 62: 1149-1154.
107. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch. Gen. Psychiatry 2004; 61: 1153-1162.
108. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J. Clin. Psychopharmacol. 1993; 13: 423-428.
109. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch. Gen. Psychiatry 1998; 55: 1133-1141.
110. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch. Gen. Psychiatry 2010; 67: 286-295.
111. van Vliet IM, den Boer JA, Westenberg HG,. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115: 128-134.
112. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B,. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study. Am. J. Psychiatry 1999; 156: 756-760.
113. Asakura S, Tajima O, Koyama T,. Fluvoxamine treatment of generalized social anxiety disorder in Japan: A randomized double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol. 2007; 10: 263-274.
114. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC,. Sertraline for social phobia: A double-blind, placebo-controlled crossover study. Am. J. Psychiatry 1995; 152: 1368-1371.
115. Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am. J. Psychiatry 2001; 158: 275-281.
116. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M,. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br. J. Psychiatry 1999; 175: 120-126.
117. Allgulander C,. Paroxetine in social anxiety disorder: A randomized placebo-controlled study. Acta Psychiatr. Scand. 1999; 100: 193-198.
118. Lader M, Stender K, Burger V, Nil R,. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: Randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety 2004; 19: 241-248.
119. Kasper S, Stein DJ, Loft H, Nil R,. Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study. Br. J. Psychiatry 2005; 186: 222-226.
120. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacol. 2004; 19: 387-396.
121. Rickels K, Mangano R, Khan A,. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol. 2004; 24: 488-496.
122. Liebowitz MR, Gelenberg AJ, Munjack D,. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry 2005; 62: 190-198.
123. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G, SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry 2005; 66: 238-247.
124. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM,. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177: 280-288.
125. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: A randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2005; 25: 580-583.
126. Schutters SI, Van Megen HJ, Van Veen JF, Denys DA, Westenberg HG,. Mirtazapine in generalized social anxiety disorder: A randomized, double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 2010; 25: 302-304.
127. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: A placebo-controlled study. J. Clin. Psychopharmacol. 1999; 19: 341-348.
128. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 2004; 24: 141-149.
129. Zhang W, Connor KM, Davidson JR,. Levetiracetam in social phobia: A placebo controlled pilot study. J. Psychopharmacol. 2005; 19: 551-553.
130. Stein MB, Ravindran LN, Simon NM, et al. Levetiracetam in generalized social anxiety disorder: A double-blind, randomized controlled trial. J. Clin. Psychiatry 2010; 71: 627-631.
131. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR,. Efficacy of olanzapine in social anxiety disorder: A pilot study. J. Psychopharmacol. 2002; 16: 365-368.
132. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR,. Quetiapine as monotherapy for social anxiety disorder: A placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007; 31: 1464-1469.
133. Ravindran LN, Kim DS, Letamendi AM, Stein MB,. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J. Clin. Psychopharmacol. 2009; 29: 561-564.
134. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B,. Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials. J.Clin.Psychiatry 2002; 63: 152-155.
135. Blanco C, Bragdon LB, Schneier FR, Liebowitz MR,. The evidence-based pharmacotherapy of social anxiety disorder. Int. J. Neuropsychopharmacol. 2013; 16: 235-249.
136. Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am. J. Psychiatry 2014; 171: 44-53.
137. Silberman EK,. The role of benzodiazepines in treating social anxiety disorder. Am. J. Psychiatry 2014; 171: 795.
138. Seedat S, Stein MB,. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J. Clin. Psychiatry 2004; 65: 244-248.
139. Acarturk C, Cuijpers P, van Straten A, de Graaf R,. Psychological treatment of social anxiety disorder: A meta-analysis. Psychol. Med. 2009; 39: 241-254.
140. Hofmann SG,. Recent advances in the psychosocial treatment of social anxiety disorder. Depress. Anxiety 2010; 27: 1073-1076.
141. Bogels SM, Wijts P, Oort FJ, Sallaerts SJ,. Psychodynamic psychotherapy versus cognitive behavior therapy for social anxiety disorder: An efficacy and partial effectiveness trial. Depress. Anxiety 2014; 31: 363-373.
142. Leichsenring F, Salzer S, Beutel ME, et al. Psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: A multicenter randomized controlled trial. Am. J. Psychiatry 2013; 170: 759-767.
143. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry 2006; 63: 298-304.
144. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry 2008; 63: 544-549.
145. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch. Gen. Psychiatry 2004; 61: 1005-1013.
146. Robins E, Guze SB,. Establishment of diagnostic validity in psychiatric illness: Its application to schizophrenia. Am. J. Psychiatry 1970; 126: 983-987.
147. Narrow WE, Rae DS, Robins LN, Regier DA,. Revised prevalence estimates of mental disorders in the United States: Using a clinical significance criterion to reconcile 2 surveys' estimates. Arch. Gen. Psychiatry 2002; 59: 115-123.